Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. The trial did not meet the pre-specified co-primary,
Cassava flunks phase 3 Alzheimer's test, triggering early end of 2nd trial and stock crash
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing secondary and exploratory biomarker endpoints, the biotech has pulled the plug on another phase 3 trial and an open-label extension.
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...
(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...
Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its ...
EST Cassava Sciences (SAVA) sinks 84% to $4.21 after Alzheimer’s study missDon't Miss our Black Friday Offers:Unlock your investing ...
AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology ...
Wall Street witnessed a historic day with the S&P 500 and Dow Jones Industrial Average reaching record highs. The Russell ...
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback